A Few Signs That Martin Shkreli Might Be In Some Trouble | Lowering the Bar


Although his smirk has not yet wavered.

Source: A Few Signs That Martin Shkreli Might Be In Some Trouble | Lowering the Bar

Greed, lies, and Shkreli’s smug “performance”: Lawmakers go ballistic


Hearing exposes Turing’s lavish spending, while exec says they’re losing money.

Source: Greed, lies, and Shkreli’s smug “performance”: Lawmakers go ballistic

Martin Shkreli’s other pharma company files for bankruptcy | Ars Technica


After firing indicted CEO, company now fights to keep shares listed on NASDAQ.

Source: Martin Shkreli’s other pharma company files for bankruptcy | Ars Technica

Martin Shkreli’s other pharma company is dramatically collapsing | Ars Technica


Following arrest of CEO, KaloBios loses CFO, accountants, is delisted from Nasdaq.

Source: Martin Shkreli’s other pharma company is dramatically collapsing | Ars Technica

Turing’s Martin Shkreli regrets 5,000% price hike—says it wasn’t high enough | Ars Technica


In a Healthcare summit hosted by Forbes on Thursday, Martin Shkreli, the founder and CEO of Turing Pharmaceuticals, admitted he made a mistake by raising the price of a decades-old drug by more than 5,000 percent. But it’s not the mistake you might expect.

Source: Turing’s Martin Shkreli regrets 5,000% price hike—says it wasn’t high enough | Ars Technica

$750/pill pharma company reverses decision to lower drug price | Ars Technica

Turing will offer hospitals and patients discounts, but high list price stands.

Source: $750/pill pharma company reverses decision to lower drug price | Ars Technica